固尔苏在早产儿生命支持中的临床应用研究
|
摘要
目的固尔苏在早产儿生命支持中的临床应用价值。方法方便选取40例早产儿,时间为2015年8月—2018年12月期间,将入选者随机分为对照组(n=20,采取常规技术生命维持)与实验组(n=20,在常规技术生命维持基础上应用固尔苏),对治疗情况及相关指标进行观察。结果实验组患儿呼吸机辅助通气时间、用氧时间、住院时间分别为(17.02±2.55)h、(9.12±1.56)d、(25.31±5.35)d,均较对照组明显缩短(t=-4.33、-8.50、-11.39,P<0.05);实验组治愈率、转院率、死亡率分别为95.0%、5.0%、0.0%,治愈率较对照组明显要高,转院率、死亡率明显要低(P<0.05);实验组并发症发生率均较对照组明显要低(P<0.05);用药后6 h,实验组患儿血气指标,PaO_2、SaO_2及PaCO_2分别为(88.65±9.55)mmHg、(94.65±4.37)%、(45.25±8.56)mmHg,均较对照组明显要优(t=3.39、4.51、-2.72,P<0.05);实验组患儿治疗后肺氧合功能,OI、a/AP(O_2)分别为(12.25±4.56)、(0.26±0.07),均显著改善,且较对照组明显要优,差异有统计学意义(t=-3.63、4.21,P<0.05)。结论对早产儿预防性使用固尔苏,为早产儿的成长提供生命支持,提高存活率,减少并发症,改善预后,值得于临床广泛推广。
Objective To study the application value of Curosurf in premature infant's life support. Methods A total of 40 premature infants treated from August 2015 to December 2018 in our hospital were convenient selected and randomly divided into control group(n=20) and observation group(n=20). The control group took the conventional life support, and the observation group took the conventional life support plus Curosurf. The therapeutic effect and index were observed. Results The assisted ventilation time, oxygen-uptaking time and hospitalization time in the observation group [(17.02±2.55)h,(9.12±1.56)d,(25.31±5.35)d] was significantly shorter than those in the control group(t=-4.33,-8.50,-11.39, P<0.05). The cure rate, transfer rate and death rate of observation group were 95.0%、5.0%、0.0%. Compared with control group, the cure rate of the observation group was high, transfer rate and death rate were low(P<0.05). The inciclence of complications in the experimental group was significantly lower than in the control group(P <0.05).The complication rate PaO_2,SaO_2,PaCO_2 were(88.65±9.55)mmHg、(94.65±4.37)%、(45.25±8.56)mmHg,in the observation group was significantly better than that in the control group(t=3.39,4.51,-2.72,P<0.05). The oxygenation function in the observation group OI、a/AP(O_2)were(12.25±4.56),(0.26±0.07),after treatment was significantly better than that in the control group.the difference was statistically significant(t=-3.63,4.21,P<0.05). Conclusion Curosurf can increase the survival rate, reduce the complication rate and improve the clinical prognosis of premature infants. It shall be widely applied in clinical practice.
Objective To study the application value of Curosurf in premature infant's life support. Methods A total of 40 premature infants treated from August 2015 to December 2018 in our hospital were convenient selected and randomly divided into control group(n=20) and observation group(n=20). The control group took the conventional life support, and the observation group took the conventional life support plus Curosurf. The therapeutic effect and index were observed. Results The assisted ventilation time, oxygen-uptaking time and hospitalization time in the observation group [(17.02±2.55)h,(9.12±1.56)d,(25.31±5.35)d] was significantly shorter than those in the control group(t=-4.33,-8.50,-11.39, P<0.05). The cure rate, transfer rate and death rate of observation group were 95.0%、5.0%、0.0%. Compared with control group, the cure rate of the observation group was high, transfer rate and death rate were low(P<0.05). The inciclence of complications in the experimental group was significantly lower than in the control group(P <0.05).The complication rate PaO_2,SaO_2,PaCO_2 were(88.65±9.55)mmHg、(94.65±4.37)%、(45.25±8.56)mmHg,in the observation group was significantly better than that in the control group(t=3.39,4.51,-2.72,P<0.05). The oxygenation function in the observation group OI、a/AP(O_2)were(12.25±4.56),(0.26±0.07),after treatment was significantly better than that in the control group.the difference was statistically significant(t=-3.63,4.21,P<0.05). Conclusion Curosurf can increase the survival rate, reduce the complication rate and improve the clinical prognosis of premature infants. It shall be widely applied in clinical practice.
引文
[1]简惠娜,陈创鑫,赵少岚,等.沐舒坦与固尔苏应用于新生儿肺透明膜病的临床疗效对比分析[J].中国妇幼保健,2016,31(11):2319-2321.
[2]陈思红,文梦灵,黄友妮,等.固尔苏联合鼻塞式持续气道正压通气治疗新生儿肺透明膜病的护理[J].护士进修杂志,2016,31(1):45-46.
[3]李巧云,卓瑞燕,程奇,等.固尔苏与NCPAP的联合应用在早产儿中应用效果评价[J].海峡药学,2017,29(11):147-149.
[4]高勤在.固尔苏气管内给药与N-CPAP联合治疗早产儿肺透明膜病疗效分析[J].中国妇幼保健,2015,30(3):483-484.
[5]阮婕,周素芽,陈超,等.固尔苏气管内滴注对新生儿呼吸窘迫综合征患儿右心功能的影响[J].中国生化药物杂志,2016,36(12):81-83.
[6]付朝阳.不同剂量固尔苏治疗晚期早产儿呼吸窘迫综合征的疗效研究[J].中国妇幼保健,2015,30(4):565-566.
[7]杨美君.固尔苏气管内给药与N-CPAP联合治疗早产儿肺透明膜病疗效分析[J].海峡药学,2015,27(11):150-151.
[8]孙静.固尔苏联合经鼻持续气道正压通气治疗新生儿呼吸窘迫综合征的疗效及其对血气指标的影响[J].黑龙江医药,2016,29(3):458-460.
[9]黄列,徐锡,纪永佳,等.布地奈德联合固尔苏对支气管肺发育不良防治的研究[J].宁夏医学杂志,2017,39(6):511-512.
[10]谭绍葵,谢彤.大剂量固尔苏联合经鼻持续正压通气在新生儿呼吸窘迫综合征初始治疗中的应用分析[J].世界临床医学,2016,10(18):133,136.
[11]朱晓洁.固尔苏联合鼻塞式气道正压通气治疗新生儿呼吸窘迫综合征的疗效及对患儿炎症因子的影响[J].黑龙江医药,2017,30(3):575-577.
[12]康华,应海燕,周卫萍,等.多中心珂立苏治疗早产儿呼吸窘迫综合征疗效的研究[J].中国妇幼保健,2015,30(6):879-881.
[13]赵明刚.固尔苏联合经鼻持续气道正压通气治疗新生儿呼吸窘迫综合征疗效分析[J].内蒙古医学杂志,2018,50(3):276-278.
[2]陈思红,文梦灵,黄友妮,等.固尔苏联合鼻塞式持续气道正压通气治疗新生儿肺透明膜病的护理[J].护士进修杂志,2016,31(1):45-46.
[3]李巧云,卓瑞燕,程奇,等.固尔苏与NCPAP的联合应用在早产儿中应用效果评价[J].海峡药学,2017,29(11):147-149.
[4]高勤在.固尔苏气管内给药与N-CPAP联合治疗早产儿肺透明膜病疗效分析[J].中国妇幼保健,2015,30(3):483-484.
[5]阮婕,周素芽,陈超,等.固尔苏气管内滴注对新生儿呼吸窘迫综合征患儿右心功能的影响[J].中国生化药物杂志,2016,36(12):81-83.
[6]付朝阳.不同剂量固尔苏治疗晚期早产儿呼吸窘迫综合征的疗效研究[J].中国妇幼保健,2015,30(4):565-566.
[7]杨美君.固尔苏气管内给药与N-CPAP联合治疗早产儿肺透明膜病疗效分析[J].海峡药学,2015,27(11):150-151.
[8]孙静.固尔苏联合经鼻持续气道正压通气治疗新生儿呼吸窘迫综合征的疗效及其对血气指标的影响[J].黑龙江医药,2016,29(3):458-460.
[9]黄列,徐锡,纪永佳,等.布地奈德联合固尔苏对支气管肺发育不良防治的研究[J].宁夏医学杂志,2017,39(6):511-512.
[10]谭绍葵,谢彤.大剂量固尔苏联合经鼻持续正压通气在新生儿呼吸窘迫综合征初始治疗中的应用分析[J].世界临床医学,2016,10(18):133,136.
[11]朱晓洁.固尔苏联合鼻塞式气道正压通气治疗新生儿呼吸窘迫综合征的疗效及对患儿炎症因子的影响[J].黑龙江医药,2017,30(3):575-577.
[12]康华,应海燕,周卫萍,等.多中心珂立苏治疗早产儿呼吸窘迫综合征疗效的研究[J].中国妇幼保健,2015,30(6):879-881.
[13]赵明刚.固尔苏联合经鼻持续气道正压通气治疗新生儿呼吸窘迫综合征疗效分析[J].内蒙古医学杂志,2018,50(3):276-278.